Introduction. O
6 -methylguanine-DNA methyltransferase (MGMT) is the DNA repair enzyme responsible for removing alkylation adducts from the O 6 -position of guanine in DNA by mechanism of so-called «suicidal» reaction [1] [2] [3] . MGMT is irreversibly inactivated after binding of alkyl group to cysteine, so the synthesis of molecules of MGMT de novo is required for further DNA repair. Despite this enzyme prevents mutations and cell death, it can provide resistance of cancer cells to alkylating agents, which are frequently used in the chemotherapy of many types of cancer [3, 4] . Thus, the expression of MGMT and its activity in human tumors can determine cell response to therapies with alkylating agents. However, levels of the MGMT expression are highly variable among normal tissues within an individual, among different tumors, between cells within a tissue or tumor, as well as between individuals within one tissue [2, 5] . The MGMT expression variation with reversible loss has been also revealed during long-term in vitro cultivation of cells [5] [6] [7] [8] [9] .
Observed variations of the MGMT expression level indicate a complicated regulation of this gene, but molecular basis of intra-and inter-individual variations is still not fully defined. Therefore, the aim of this paper is to review epigenetic factors which could be potentially involved in regulation of the human MGMT expression.
This article is the first part of a thematic series on regulation of MGMT expression and is devoted to the epigenetic regulation. The next two parts are about genetic factors regulating MGMT expression.
Epigenetic regulation of gene expression includes several mechanisms, in particular DNA methylation, histone packaging and modifications, RNA-based mechanisms, post-translational modifications of protein, and other factors. To date, the Encyclopedia of DNA Elements (ENCODE) Consortium aims to build a comprehensive data list of functional regulatory elements in the human genome which is freely available for download and analysis [10] . Most of discussed in this review experimental data, related to regulatory elements within human MGMT, were taken from ENCODE project at the UCSC Genome Browser (the University of California Santa Cruz, http://genome.ucsc.edu/), Genome Reference Consortium Human Build 37 (GRCh37, or hg19 assembly, submitted in February 2009) [10, 11] . O 6 -alkylguanine-DNA alkyltransferases. During lifespan cells are under the influence of different endogenous and exogenous stress factors, which can damage the genomic DNA including the alkylation. The various sites of alkylation have been revealed, but alkylation of guanine at the O 6 -position, in despite of its minority, is cytotoxic, has the strongest mutagenic potential, as well as can cause tumor development [2, 12, 13] . Different pathways of DNA repair were evolved in mammalian cells for self-defence from toxic and mutagenic effects [14] . O 6 -Alkylguanine-DNA alkyltransferase (official name O 6 -methylguanine-DNA methyltransferase, MGMT) is the DNA repair enzyme responsible for removing alkylation adducts from DNA [1] [2] [3] . The alkyltransferases are widely expanded among over 100 different species from Archaea and Bacteria to many organisms of Eukarya including humans, but not in Plantae, fission yeast Schizosaccharomyces pombe and bacterium Deinococcus radiodurans [15] . At the same time MGMT is highly conservative that evidences this alkyltransferase has a great importance for genomic integrity (see alignments of sequences of the alkyltransferase and alkyltransferase like proteins in reviews [5, 15] ).
This enzyme belongs to the direct repair pathway, it removes alkyl groups (such as methyl-, ethyl-, chloroethyl-group a. o.) without DNA lesion transferring them to an own cysteine residue by mechanism of the socalled «suicidal» reaction, namely MGMT is irreversibly inactivated after binding alkyl group to cysteine, so the synthesis of MGMT molecules de novo is required for further DNA repair. The capacity of cells to repair the O 6 -alkylguanine depends on the level of MGMT in cell or the rate at which a cell can synthesize this enzyme. Though MGMT prevents mutations and cell death, this enzyme can provide resistance of cancer cells to alkylating agents, which are frequently used in the chemotherapy of many types of cancer [3, 4] .
Thus, the expression of MGMT and its activity in human tumors can determine cell response to therapies with alkylating agents.
Intra-and inter-individual variations of MGMT expression. The MGMT gene is ubiquitously expressed in mammals, but the level of its expression widely varies depending on the type of cell or tissue, cell cycle phase, developmental stage of organism, as well as on species [2, 5, 16] . For example, a high level of the interand intra-individual variability of the MGMT expression has been revealed in peripheral blood mononuclear cells from healthy individuals [17] . A substantial variation of the amount of MGMT activity has been also revealed in all examined normal and tumor tissues from rats and humans, as well as individual MGMT variations in the human samples [16] . Variation of the MGMT activity level in human normal and tumor tissues, as well as in human lymphocytes is reviewed in [5] .
The tissue-specific variation of the human MGMT activity has been shown. For example, the highest level of expression was usually detected in the liver, followed by the colon and lung, and low -in the brain and myeloid tissues [5, 16, 18] , while the lowest expression was detected in hematopoietic (CD34 + ) progenitor cells [2] . In tumors the highest level of MGMT expression was observed in the breast, colon, lung and ovarian tumors, and the lowest -in the gliomas, malignant melanomas, pancreatic carcinomas and testis tumors [2] .
The MGMT expression is widely varied in immortalized mammalian cells. It has been supposed that this variability in cultered cells reflects the MGMT expression level in the tissue from which they were obtained [5, 8] . For example, such correlation was revealed for the cell lines of lymphoblastoid cells derived from the peripheral blood lymphocytes [6] . Moreover, it has been shown that levels of the MGMT vary during long-term in vitro cultivation of cells [6, 9] , and decrease in the MGMT expression can be reversible [7] . In particular, the lymphoblastoid cell lines are loosing the MGMT activity compared with the cells at early passages of in vitro cultivation [8] . Cell cycle dependent variation of MGMT in cultured mammalian cells is discussed in [5] . In our investigations fluctuations of MGMT protein level during long-term in vitro cultivation of the cell lines derived from mouse embryonic germ cells has been also revealed [9] .
Epigenetic regulation of the MGMT expression. Observed variations of the MGMT expression indicate a complicated regulation of this gene. Genetic, epigenetic and environmental factors may affect the gene expression, and the human MGMT gene is no exception.
Epigenetic changes can concern chromatin structure via histone modifications and methylation of promoter region and gene body, as well as RNA interference, alternative splicing, and post-translational modifications of the MGMT protein.
DNA methylation and chromatin remodeling. T h e MGMT p r o m o t e r c o n t a i n s t h e CpG i s l a n d (CGI).
A predicted CGI is located at position chr10: 131264949-131265710 in hg19/Human [10] . The size of CGI is 762 bps. It contains 75 CpG dinucleotides and overlaps with the transcription start site (TSS) and 5'-flanking sequence of the gene (Fig. 1 ). The location of TSSs helps to define the promoter regions. TSS of the human MGMT gene ( Fig. 1 ) was determined by Switch Gear Genomics by integrating experimental data using an empirically derived scoring function [10] . This TSS (CHR10_P0807_R1) has position chr10:131265479 in the plus-strand DNA of 10q26 chromosome band, whereas the RefSeq MGMT gene is located at chr10: 131265454-131565783 (NM_002412) [10] .
CGIs are typically common near or overlapping TSSs and may be associated with promoter regions [19] . In case of the MGMT promoter TSS is located within detected CGI. Approximately 70 % of promoters of vertebrates contain CGI, mainly they are promoters of virtually all housekeeping genes, as well as a part of tissue-specific genes and developmental regulator genes [20] . According to promoter types indicated in [19] , so-called housekeeping genes with broad expression throughout organismal cycle have promoters of ubiquitous type, which are characterized by dispersed TSSs and ordered nucleosome configuration; they are TATA-depleted and have CGIs. The promoter region of human MGMT gene is known to be GC-rich and TATA-free [21] . Since promoters function as sites of transcription initiation by binding and correct positioning of the transcription initiation complex [19] , the binding of transcription factors (TFs) with cis-regulatory elements within promoter alters the local chromatin structure, creating open chromatin regions [22] . These regions can be identified by deoxyribonuclease I (DNaseI) hypersensitive site (DHS) mapping [22] . DHS tracks in Fig. 1 display the location of active cis-regulatory elements identified as open chromatin within promoter region of the MGMT gene in different cell lines [10] . Three DNase clusters are shown from this track in Fig. 1 [10] .
Thus, as shown in Fig. 1 , the promoter region of human MGMT gene contains TSS, which is located within CGI, DHS and exon 1 of the gene. Overlapping of CGI and DHS marks the open chromatin region and the location of active cis-regulatory elements. The ENCODE studies of different cell lines demonstrated that MGMT promoter can be targeted by several TFs in this region (Fig. 1) . The track of TF ChIP-seq shows regions where TFs bind to DNA as assayed by ChIP-seq (chromatin immunoprecipitation (ChIP) assay in combination with sequencing).
The track in Fig. 2 , B (see inset), shows nucleosome position by MNase-seq in the MGMT promoter region in K562 cell line [10] . DHS, which overlaps with CGI and TFs binding regions, lies in a linker DNA area and is framed by nucleosomes (Fig. 1, Fig. 2 , see inset), thus, providing accessibility of DNA to regulatory proteins in the cells expressing gene. It is well known that DNA methylation at the CGI of promoters plays a key role in the epigenetic silencing of tumor suppressor genes. It was shown that MGMT is epigenetically silenced in various human cancer types, too. It is demonstrated on an example of more than 500 primary human tumors, cancer cell lines, and normal tissues that hypermethylation of the MGMT promoter, associated with the loss of expression, is frequent [23, 24] . Among examined human neoplasias, the MGMT hypermethylation was found in about 40 % of brain tumors and colorectal carcinomas. Approximately 25 % of nonsmall cell lung carcinomas, lymphomas, and head and neck carcinomas also showed the MGMT hypermethylation, while some types of tumors had infrequent the MGMT promoter methylation (e. c. pancreatic carcinomas, melanomas, renal carcinomas, acute leukemias, bladder carcinomas) or had not at all the MGMT methylation in other cancer types (e. c. carcinomas of breast, endometrium, ovary, liver, small cells of lung) [24, 25] .
It has been shown that immortal cell lines with the methylated MGMT promoter are more sensitive to alkylating agents [26] , and the MGMT-deficient tumors with the methylated promoter also show an increased sensitivity to such drugs [27] . The MGMT promoter methylation was revealed to be associated with the tumor regression and prolonged overall and disease-free survival of 40 % of patients with gliomas, which had the methylated promoter and were treated with the alkylating agent carmustine (or BCNU) [27] . The MGMT promoter hypermethylation was shown to correlate with a statistically significant increase in survival of patients with diffuse large B-cell lymphoma after treatment with cyclophosphamide as part of multidrug regimen, too [28] . Thereby, it seems that the MGMT promoter methylation can be a useful clinical predictive marker of the responsiveness of tumors to alkylating agents and patient survival [28] [29] [30] . However, the MGMT gene silencing in tumors causes an accumulation of point mutations resulting in genomic instability and determining disease outcome [31] . For example, it has been revealed that the MGMT promoter methylation was significantly associated with point mutations of the K-ras gene in patients with gastric carcinoma, as well as with patient survival [32] .
Methylation of cytosines in the body of the MGMT gene and in its promoter results in opposite effects. For example, methylation of promoter region is associated with the loss of MGMT expression [23, 33, 34] , whilst methylation of downstream sequences in the gene body correlates with an increased expression [33, 35, 36] . It has been shown that most gene bodies are CpG-poor and extensively methylated, that is a feature of transcribed genes and is not associated with repression of transcription elongation [37] . The MGMT body does not contain any predicted CGI (accordingly to the general CGI criteria) and is methylated, for example, in HepG2 cell line expressing this gene (Fig. 2, A, see inset) , and this observation is consistent with a feature of actively transcribed genes [37] . Possible functions of the gene body methylation are discussed in [37] .
Also, it has been demonstrated that the methylation of CGI of MGMT is associated with the gene suppression, and it is generally incomplete, localizing in a core promoter region around TSS, creating hot spots of methylation [23] .
C h r o m a t i n s t r u c t u r e r e l a t e d t o t h e m e t h y l a t i o n o f t h e MGMT p r o m o t e r.
Silencing the CGI-containing genes is correlated with increased cytosine methylation, closed chromatin structure, and exclusion of TF binding in the CGI of promoters [37] . Many studies indicate that the methylation of CpGs represses the transcription via recruitment of histone deacetylase complexes by methyl-CpG binding proteins, and as consequence the chromatin condensation [37] . It has been reported that histone deacetylation plays a role in the MGMT silencing, too [38, 39] .
The importance of histone modifications in epigenetic regulation of the human MGMT gene, such as acetylation and methylation of residues, due to chromatin structure changes was shown in many studies. In particular, inactivation of the MGMT gene transcription was demonstrated to be associated with the loss of open chromatin structure and exclusion of TFs from Sp1-like binding sites within the CGI, but not with methylation of the TF binding region [40] . The chromatin condensation after CGI methylation in promoter region and consequent complete blockage of the MGMT gene expression were shown in other studies by using a luciferase reporter system [38] , an analysis of accessibility of restriction enzymes to the MGMT promoter [41, 42] a. o. All of them are consistent with a model of methylationrelated silencing of gene expression, which involves binding of methyl-CpG binding protein to methylated DNA, recruitment by this protein of histone deacetylase complexes, and as consequence histone deacetylation and chromatin condensation [38] .
It has been shown by using ChIP assay that a higher level of acetylation of histones H3 and H4 bound to the promoter region was associated with the MGMT gene expression, while transcriptional inactivation of the gene was caused by formation of condensed chromatin after binding of a greater amount of methyl-CpG binding domain containing proteins (such as MeCP2, MBD1, and CAF-1) to the methylated promoter and histone deacetylation [39] .
It has been revealed that associated with open chromatin and active transcription acetylated H3K and H4K, as well as methylated H3K4, were localized outside of the unmethylated CGI whithin minimal promoter in the MGMT-expressing cells, whilst closed chromatin was associated with methylated CGI and hypermethylated lysine 9 in histone H3 (H3K9) throughout this island [43, 44] . This observation is consistent with a model for the aberrant silencing of the human MGMT gene, in accordance with which the open chromatin structure of CGI in MGMT-expressing cells consists of an approximately 250-bp nucleosome-free, TF binding and nuclease-accessible region of DNA, and is formed by at least four flanking precisely positioned nucleosome-like structures [42] . Such positioning of nucleosomes is lost and random in MGMT non-expressing cells causing the closed chromatin structure [42] . Thus, in MGMT non-expressing cells the closed chromatin structure is associated with methylated CGI and hypermethylated H3K9 throughout this island [43] . Dimethylation of H3K9 and binding of methyl-CpG binding protein have been shown to be common and essential for MGMT silencing in cases with hypomethylated promoter region [44] .
An example of open chromatin state is shown in Fig. 3 (see inset) . Histone modification tracks from ENCODE project [10] display signals for markers of active promoter, such as H3K4me3, H3K9ac, and H3K27ac in MGMT-expressing HepG2 cells, whereas there is no signal for markers of silenced chromatin regions (H3K9me3 and H3K27me3).
A causality between the MGMT promoter methylation and its transcriptional silencing was demonstrated also in cultured cells [26, 45, 46] . It was shown that logarithmically growing normal human fibroblasts displayed approximately 15 % of CpG dinucleotide methylation in CGI of the MGMT promoter, compared with approximately 50 % of CGI methylation in confluent growth-arrested cells [45] . The MGMT promoter methylation was shown to be not permanent and reversed at logarithmic growth of cells [45] . Progressive increasing of the CGI methylation of the MGMT promoter region was demonstrate with increasing of cell culture passage number, so established immortalized cell lines often completely lack of the gene expression [26, 46] . These findings probably could explain our and other researchers observations of fluctuations of MGMT levels at different stages of in vitro cultivation and establishment of cell lines [9] .
RNA i n t e r f e r e n c e is evolutionarily conserved and widespread mechanism regulation of gene expression by small noncoding RNAs [47, 48] . MicroRNAs (miRNAs) have been identified as one of the most widespread class of endogenous small RNAs in mammalian cells [48] . Sites for many miRNA from different families are predicted in the 3'UTR of MGMT transcript NM_002412 by using TargetScanHuman 5.1 on its webpage [47] , as well as in the UCSC Genome Browser (Table) . To date there is no evidence about regulation of the human MGMT gene expression in vivo via RNA interference mechanism, but silencing of the MGMT protein biosynthesis via RNA interference belongs to the strategies to increase the sensitivity of cancer cells to alkylating drugs. Small double-stranded RNA molecules can be introduced exogenously as short interfering RNAs [14] . The clinical use of such strategy is suggested, but it is prevented by significant problems, among which are incomplete silencing of a target gene and so-called off-target effects, non-specific immune responses, and a major challenge -in vivo delivery. A l t e r n a t i v e s p l i c i n g of genes is an important mechanism of the post-transcriptional regulation of gene expression in metazoan, generating different transcripts from a single pre-mRNA [49] . The alternative MGMT transcripts were predicted by Swiss Institute of Bioinformatics (NC_000010_1953). The UCSC alternative splicing track is constructed by analyzing experimental RNA transcripts (Fig. 4) , but no one alternatively spliced isoform was transcribed from the MGMT gene [50] according to the Alternative Splicing Annotation Project [51] . Thus, the expression of alternative MGMT transcripts must be shown in experiments of transcriptome profiling by using not only hybridization-based microarrays, but next generation sequencing based approach, RNA-seq, and so on [52] .
Post-translational modifications of the MGMT protein and their influence upon the enzyme fate are extensively reviewed and discussed in [50] .
Conclusions. The DNA repair enzyme MGMT belongs to the direct reversal repair system, i. e. removes alkyl groups from the O 6 -position guanine without DNA lesion by mechanism of so-called «suicidal» reaction, and the capacity of cells to repair O 6 -alkylguanine depends on the level of MGMT in cell or the rate at which a cell can synthesize it. However, MGMT not only prevents mutations and cell death, but the enzyme can provide resistance of cancer cells to alkylating chemotherapy. The high intra-and inter-individual variations in the human MGMT expression level have been observed indicating a complicated regulation of this gene. In this study the epigenetic factors, which could be potentially 
